NASDAQ:GLPG - GALAPAGOS NV/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GALAPAGOS NV/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $227.27 -4.09 (-1.77 %) (As of 01/27/2020 04:00 PM ET) Add Compare Today's Range$226.52Now: $227.27▼$229.0650-Day Range$205.44MA: $214.91▼$238.6852-Week Range$94.75Now: $227.27▼$242.38Volume103,095 shsAverage Volume141,129 shsMarket Capitalization$12.46 billionP/E Ratio44.92Dividend YieldN/ABeta1.58 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLPG Previous Symbol CUSIPN/A CIK1421876 Webhttp://www.glpg.com/ Phone321-534-2900Debt Debt-to-Equity Ratio0.01 Current Ratio8.95 Quick Ratio8.95Price-To-Earnings Trailing P/E Ratio44.92 Forward P/E Ratio32.28 P/E GrowthN/A Sales & Book Value Annual Sales$375.54 million Price / Sales33.18 Cash FlowN/A Price / Cash FlowN/A Book Value$27.99 per share Price / Book8.12Profitability EPS (Most Recent Fiscal Year)($0.66) Net Income$-34,560,000.00 Net Margins32.09% Return on Equity25.34% Return on Assets15.38%Miscellaneous EmployeesN/A Outstanding Shares54,820,000Market Cap$12.46 billion Next Earnings Date4/3/2020 (Estimated) OptionableOptionable Receive GLPG News and Ratings via Email Sign-up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:GLPG Rates by TradingView GALAPAGOS NV/S (NASDAQ:GLPG) Frequently Asked Questions What is GALAPAGOS NV/S's stock symbol? GALAPAGOS NV/S trades on the NASDAQ under the ticker symbol "GLPG." When is GALAPAGOS NV/S's next earnings date? GALAPAGOS NV/S is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for GALAPAGOS NV/S. What price target have analysts set for GLPG? 15 equities research analysts have issued twelve-month price targets for GALAPAGOS NV/S's stock. Their forecasts range from $130.00 to $215.00. On average, they anticipate GALAPAGOS NV/S's stock price to reach $181.80 in the next year. This suggests that the stock has a possible downside of 20.0%. View Analyst Price Targets for GALAPAGOS NV/S. What is the consensus analysts' recommendation for GALAPAGOS NV/S? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GALAPAGOS NV/S in the last year. There are currently 8 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GALAPAGOS NV/S. What are Wall Street analysts saying about GALAPAGOS NV/S stock? Here are some recent quotes from research analysts about GALAPAGOS NV/S stock: 1. According to Zacks Investment Research, "Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. " (1/10/2020) 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our 12-month, $150 price target on shares of Galapagos is derived from a 13- year DCF-based, sum-of-the-parts analysis. Our DCF is driven by: beta of 1.34, terminal growth rate of -3.0%, risk premium of 4.93%, calculated WACC of 9.3%, and tax rate of 20% beginning in FY 2025. (11%) together make up 88% of our value, with the remainder derived from the probability-adjusted, filgotinib-associated milestone payments." (6/12/2019) 3. Cantor Fitzgerald analysts commented, "Our Galapagos thesis: We think that 2019 is the year filgotinib will differentiate itself among the JAKs. We reiterate our Overweight and price target of $130. We expect key Phase 3 data from filgotinib in studies called FINCH 1 and 3 in 1Q19. We think that these data may reveal that filgotinib has an attractive risk/benefit profile among the JAK inhibitors. Section may be found on pages 4 – 5.We value Galapagos shares on a probability-adjusted DCF." (5/2/2019) Has GALAPAGOS NV/S been receiving favorable news coverage? Media stories about GLPG stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. GALAPAGOS NV/S earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for GALAPAGOS NV/S. Who are some of GALAPAGOS NV/S's key competitors? Some companies that are related to GALAPAGOS NV/S include Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), UCB (UCBJF), GRIFOLS S A/S (GRFS), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA) and Beigene (BGNE). What other stocks do shareholders of GALAPAGOS NV/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other GALAPAGOS NV/S investors own include Gilead Sciences (GILD), argenx (ARGX), CELYAD SA/ADR (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Pharming Group (PHGUF), Collegium Pharmaceutical (COLL), Trade Desk (TTD), Sociedad Quimica y Minera de Chile (SQM) and Celgene (CELG). Who are GALAPAGOS NV/S's key executives? GALAPAGOS NV/S's management team includes the folowing people: Mr. Onno van de Stolpe, Co-Founder, MD, CEO & Exec. Director (Age 60)Mr. Bart Filius MBA, CFO & COO (Age 49)Dr. Piet Wigerinck, Chief Scientific Officer (Age 55)Ms. Elizabeth Goodwin, VP of Investor Relations & Corp. CommunicationsDr. Andre Hoekema, Chief Bus. Officer (Age 62) When did GALAPAGOS NV/S IPO? (GLPG) raised $161 million in an initial public offering on Thursday, May 14th 2015. The company issued 3,800,000 shares at a price of $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers. Who are GALAPAGOS NV/S's major shareholders? GALAPAGOS NV/S's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (0.12%), Henry James International Management Inc. (0.04%), Eqis Capital Management Inc. (0.04%), Campbell & CO Investment Adviser LLC (0.00%) and FNY Investment Advisers LLC (0.00%). Which institutional investors are selling GALAPAGOS NV/S stock? GLPG stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Eqis Capital Management Inc.. Which institutional investors are buying GALAPAGOS NV/S stock? GLPG stock was bought by a variety of institutional investors in the last quarter, including Henry James International Management Inc., Campbell & CO Investment Adviser LLC and FNY Investment Advisers LLC. How do I buy shares of GALAPAGOS NV/S? Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is GALAPAGOS NV/S's stock price today? One share of GLPG stock can currently be purchased for approximately $227.27. How big of a company is GALAPAGOS NV/S? GALAPAGOS NV/S has a market capitalization of $12.46 billion and generates $375.54 million in revenue each year. The biotechnology company earns $-34,560,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis. View Additional Information About GALAPAGOS NV/S. What is GALAPAGOS NV/S's official website? The official website for GALAPAGOS NV/S is http://www.glpg.com/. How can I contact GALAPAGOS NV/S? GALAPAGOS NV/S's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected] MarketBeat Community Rating for GALAPAGOS NV/S (NASDAQ GLPG)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 405 (Vote Outperform)Underperform Votes: 351 (Vote Underperform)Total Votes: 756MarketBeat's community ratings are surveys of what our community members think about GALAPAGOS NV/S and other stocks. Vote "Outperform" if you believe GLPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLPG will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: Certificate of Deposit (CD) For Risk Adverse Investors?
